Acromegaly Update podcast

Acromegaly Update — Monday October 5, 2026

0:00
7:00
Rewind 15 seconds
Fast Forward 15 seconds
A thin week: no top-tier-journal acromegaly papers appeared, so Part A draws on the next tier (a radiomics model to predict somatostatin-analog response, a familial Carney-complex case, and bone proteomics), while the rare disease industry's big story is uniQure's four-year Huntington's gene therapy data, which showed a smaller, non-significant benefit and sent the stock down about 40%.

More episodes from "Acromegaly Update"